User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network

Primary tabs

Lacombe, Denis [UCL] Butler-Smith, A Therasse, Patrick Fumoleau, P Burtles, S Verweij, J.

From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations hake all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

Document type Article de périodique (Journal article) – Synthèse de littérature
Publication date 2003
Language Anglais
Journal information "Cancer Investigation" - Vol. 21, no. 1, p. 137-147 (2003)
Peer reviewed yes
Publisher Marcel Dekker Inc (New York)
issn 0735-7907
e-issn 1532-4192
Publication status Publié
Affiliation UCL
Keywords European Drug Development Network ; clinical trials ; cancer research ; new drugs
Links
  1. Finlay G.J., Riou J.-F., Baguley B.C., From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives, 10.1016/0959-8049(95)00604-4
  2. Baguley Bruce C., Finlay Graeme J., Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS, 10.1111/j.1440-1681.1995.tb01943.x
  3. Wall Monroe E., Wani M. C., Cook C. E., Palmer Keith H., McPhail A. T., Sim G. A., Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2, 10.1021/ja00968a057
  4. Bos A.M.E., Proc. Am. Soc. Clin. Oncol., 19, 768 (2000)
  5. Rothemberg M.L., Proc. Am. Soc. Clin. Oncol., 19, 769 (2000)
  6. D'Incalci M., Eur. J. Cancer, 31, 26 (1995)
  7. Erba E., Clin. Cancer Res., 6, 4508s (2000)
  8. Patterson Laurence H., Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent, 10.1007/bf00689805
  9. Raleigh S.M, Wanogho E, Burke M.Danny, McKeown S.R, Patterson L.H, Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone DI-N-oxide prodrug, 10.1016/s0360-3016(98)00308-3
  10. Chua M.-S., Cancer Res., 60, 5196 (2000)
  11. Pohl J., Bertram B., Hilgard P., Nowrousian M. R., Stüben J., Wießler M., D-19575—a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport, 10.1007/s002800050248
  12. Veyhl M., Wagner K., Volk C., Gorboulev V., Baumgarten K., Weber W.-M., Schaper M., Bertram B., Wiessler M., Koepsell H., Transport of the new chemotherapeutic agent  -D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1, 10.1073/pnas.95.6.2914
  13. Farrell N., Proc. Am. Assoc. Cancer Res., 38, 310 (1997)
  14. Bollag D., Cancer Res., 55, 2325 (1995)
  15. Bishop W. Robert, Bond Richard, Petrin Joanne, Wang Lynn, Patton Robert, Doll Ronald, Njoroge George, Catino Joseph, Schwartz Jerome, Windsor William, Syto Rosalinda, Schwartz Jeffrey, Carr Donna, James Linda, Kirschmeier Paul, Novel Tricyclic Inhibitors of Farnesyl Protein Transferase : BIOCHEMICAL CHARACTERIZATION AND INHIBITION OF Ras MODIFICATION IN TRANSFECTED Cos CELLS, 10.1074/jbc.270.51.30611
  16. Pettit G. R., Singh S. B., Hamel E., Lin C. M., Alberts D. S., Garcia-Kendal D., Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4, 10.1007/bf01954881
  17. Pettit George R., Cragg Gordon M., Herald Delbert L., Schmidt Jean M., Lohavanijaya Prasert, Isolation and structure of combretastatin, 10.1139/v82-202
  18. Denekamp Juliana, Hill Sally, Angiogenic attack as a therapeutic strategy for cancer, 10.1016/0167-8140(91)90196-n
  19. Bibby M. C., Double J. A., Loadman P. M., Duke C. V., Reduction of Tumor Blood Flow by Flavone Acetic Acid: A Possible Component of Therapy, 10.1093/jnci/81.3.216
  20. Zwi L. Jonathan, Baguley Bruce C., Gavin John B., Wilson William R., Blood Flow Failure as a Major Determinant in the Antitumor Action of Flavone Acetic Acid, 10.1093/jnci/81.13.1005
  21. Mahadevan V., Cancer Res., 50, 5537 (1990)
  22. Rewcastle Gordon W., Atwell Graham J., Baguley Bruce C., Calveley Stephen B., Denny William A., Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo, 10.1021/jm00124a012
  23. Rewcastle Gordon W., Atwell Graham J., Baguley Bruce C., Boyd Maruta, Thomsen Lindy L., Zhuang Li, Denny William A., Potential antitumor agents. 63. Structure-activity relationships for side-chain analogs of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid, 10.1021/jm00113a027
  24. ASANO MAKOTO, YUKITA AYAKO, MATSUMOTO TOMOE, HANATANI MITSUYA, SUZUKI HIDEO, An Anti-Human VEGF Monoclonal Antibody, MV833, That Exhibits Potent Anti-Tumor ActivityIn Vivo, 10.1089/hyb.1998.17.185
  25. Presta L., Cancer Res., 57, 4593 (1997)
  26. JENKINS B. J., NAUTH-MISIR R. R., MARTIN J. E., FOWLER C. G., HOPE-STONE H. F., BLANDY J. P., The Fate of G3pT1 Bladder Cancer, 10.1111/j.1464-410x.1989.tb05319.x
  27. QUILTY P. M., DUNCAN W., Treatment of Superficial (T1) Tumours of the Bladder by Radical Radiotherapy, 10.1111/j.1464-410x.1986.tb09015.x
  28. Hodge James W., Schlom Jeffrey, Donohue Susan J., Tomaszewski Joseph E., Wheeler Clyde W., Levine Barry S., Gritz Linda, Panicali Dennis, Kantor Judy A., A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate, 10.1002/ijc.2910630215
  29. Hodge J.W., Cancer Res., 55, 3598 (1995)
  30. Walboomers J.M.M., DeRoda Husman A.M., Van Den Brule A.J.C., Sniljders P.J.F., Meijer G.J.L.M. Human Papillomaviruses and Cervical Cancer: Biology and Immunology, P.L. Stern, M.A. Stanley. Oxford University Press, Oxford 1994; 41–71
  31. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF, A cytotoxic agent can be generated selectively at cancer sites, 10.1038/bjc.1988.293
  32. Bagshawe KD, The First Bagshawe lecture: Towards generating cytotoxic agents at cancer sites, 10.1038/bjc.1989.270
  33. Bagshawe Kenneth D., Antibody-Directed Enzyme Prodrug Therapy (ADEPT), Advances in Pharmacology (1993) ISBN:9780120329243 p.99-121, 10.1016/s1054-3589(08)60935-7
  34. Eck Jurgen, Langer Martin, Mockel Babette, Witthohn Klaus, Zinke Holger, Lentzen Hans, Characterization of recombinant and plant-derived mistletoe lectin and their B-chains, 10.1046/j.1432-1327.1999.00784.x
  35. Whitesell L., Mimnaugh E. G., De Costa B., Myers C. E., Neckers L. M., Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation., 10.1073/pnas.91.18.8324
  36. Schulte Theodor W., Neckers Leonard M., The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin, 10.1007/s002800050817
  37. Dolan M. E., Moschel R. C., Pegg A. E., Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents., 10.1073/pnas.87.14.5368
  38. Dolan M.E., Cancer Commun., 2, 371 (1990)
  39. Dolan M.E., Cancer Res., 51, 3367 (1991)
  40. Bradshaw TD, Shi D-F, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, Stevens MFG, Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo, 10.1038/bjc.1998.510
  41. Bradshaw TD, Wrigley S, Shi D-F, Schultz RJ, Paull KD, Stevens MFG, 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity, 10.1038/bjc.1998.122
  42. Chua M.S., Contributions to Oncology, 54, 397 (1999)
Bibliographic reference Lacombe, Denis ; Butler-Smith, A ; Therasse, Patrick ; Fumoleau, P ; Burtles, S ; et. al. Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network. In: Cancer Investigation, Vol. 21, no. 1, p. 137-147 (2003)
Permanent URL http://hdl.handle.net/2078.1/41174